All In Biotech

Drug Trial Radar · NCT05630794

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

Phase I Trial of ONC201 for Chemoprevention of Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Oct 6, 2025

Primary completion

Jul 1, 2028

Study completion May 1, 2029

Sponsor

Sponsor type
NIH
First posted
Nov 30, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase I trial is to test the safety and cancer preventive effects of different doses of ONC201 in people with familial adenomatous polyposis (FAP) or a history of multiple polyps. People with familial adenomatous polyposis (FAP) or a history of multiple polyps are at higher than average risk of developing colorectal cancer. ONC201, now known as dordaviprone, is a drug that may stop cancer cells from growing. This drug has been shown in previous studies to cause cancer cell death but not harm normal cells. If successful, this study may help us develop a new option for colorectal cancer prevention.

Conditions

  • Colorectal Adenomatous Polyp
  • Colorectal Carcinoma
  • Familial Adenomatous Polyposis
  • Multiple Adenomatous Polyps

Interventions

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood

  • ColonoscopyProcedure

    Undergo colonoscopy

  • Dordaviprone HydrochlorideDrug

    Given PO

  • Endoscopic ProcedureProcedure

    Undergo lower endoscopic evaluation

  • Questionnaire AdministrationOther

    Ancillary studies

  • SigmoidoscopyProcedure

    Undergo sigmoidoscopy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with unacceptable toxicityTime frame: Up to 35 days post last dose of ONC201

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Not yet recruiting

  • Cleveland Clinic Foundation

    Cleveland, Ohio · Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.